Astra vaccine response more with up to 10-month gap, third dose: Study

Booster given six months after the 2nd dose beneficial, shows Oxford research

Covid vaccine
The study found that antibodies induced after a single dose survived to some extent after one year.
BloombergNYT
3 min read Last Updated : Jun 29 2021 | 12:03 AM IST
Immune responses to the AstraZeneca Covid-19 vaccine improve with a longer gap of about 10 months between doses, and a third shot can boost antibody levels even further, according to a study.
 
Extending the gap between the first and second doses increased the level of protective antibodies, according to research from the University of Oxford published Monday. The researchers were also able to show for the first time that a booster given more than six months after the second dose induced a strong response and increased activity against variants.
 
Many governments are grappling with vaccine shortages and questions such as whether to give booster shots to ensure hospitals aren’t overwhelmed this winter. The results may help countries determine whether to stretch their supplies by waiting to give second doses, while showing the way to improve protection — without completely redesigning vaccines — using a third dose. Most nations have recommended a gap of 4 weeks to 12 weeks between Astra vaccines currently.
 
“This is about preparedness,” Andrew Pollard, lead investigator on the Oxford vaccine trials, said at a press briefing Monday. This data show “we can boost responses giving another dose of the AstraZeneca-Oxford vaccine and that’s really important.”
 
More research on the duration of immunity from two doses and protection against variants would help determine whether booster doses are really needed, Pollard said.
 
The study found that antibodies induced after a single dose survived to some extent after one year. Still, after 180 days the levels were half those seen at the 28-day peak. A second dose increased antibody levels between four- and 18-fold by one month after the shot, however. Volunteers in the latest study were drawn from Oxford’s original early and late-stage trials for the vaccine last year.
 
Immune response of Astra  shot boosted by mixing dose schedule with Pfizer jab
 

A mixed schedule of vaccines where a shot of Pfizer's Covid-19 vaccine is given four weeks after a AstraZeneca shot will produce better immune responses than giving another dose of the AstraZeneca shot, the Oxford study said. In any combination, they produced high concentrations of antibodies against the coronavirus spike protein.
 
Pfizer, Moderna may offer lasting protection
 
The vaccines made by Pfizer-BioNTech and Moderna set off a persistent immune reaction in the body that may protect against the coronavirus for years, scientists reported on Monday. The findings add to growing evidence that most people immunized with the mRNA vaccines may not need boosters, so long as the virus and its variants do not evolve much beyond their current forms — which is not guaranteed.
 
 

Malaysia unveils $36-bn package as curbs extended
 
Malaysia unveiled a 150 billion ringgit ($36 billion) package to help people through a nationwide lockdown that was extended for a second time with Covid infections still elevated.
 
The plan includes a 10 billion ringgit direct fiscal injection and will result in the government disbursing 10 billion ringgit in cash aid to the people by the end of the year, Prime Minister Muhyiddin Yassin said on Monday. Those applying for a six-month moratorium on loan repayments will be given automatic approval, regardless of their income status, he added.
 

The announcement marks the fourth stimulus package announced by the government this year. It comes a day after Muhyiddin said Malaysia will remain under a lockdown — in place since June 1 — after the country counted 5,218 new Covid cases Monday, above the 4,000 level the government had set for easing curbs.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineAstraZeneca

Next Story